Google
English
French
German
Italian
Japanese
Portuguese
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Acoramidis Reduces All-Cause, Cardiovascular Mortality at 30 Months in ATTR-CM
The 30-month results of the phase 3 ATTRibute-CM trial provide the latest insight into the effects of acoramidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM) ahead of a potential regulatory submission for the agent.
Presented during a hot line session at the European Society of Cardiology (ESC) Congress 2023, results of the trial suggest the acoramidis cohort experienced an 81% survival rate at 30 months, with additional analysis suggesting use of acoramidis was associated with a 30% reduction in risk of cardiovascular death relative to placebo therapy.1
myBinderRelated Content
-
ISA 2020 | 99mTc-DPD Scintigraphy Predicts Amyloid Fibril Type in ATTR Amyloidosishttps://www.youtube.com/watch?v=losWZBVV...
-
Ronglih Liao, PhDRonglih Liao is Co-Director of the Stanf...
-
Mazen Hanna, MDDr. Mazen Hanna is a cardiologist at the...
-
Amyloid Center, Stanford Health CareThe Amyloidosis center at Stanford Healt...
-
Psychopathological Dimensions in Subjects With Hereditary ATTR V30M Amyloidosis and Their Relation With Life Events ...Background: Chronic physical illness ha...
-
Future AL Amyloidosis Treatmenthttps://www.youtube.com/watch?v=K25lurau...
-
How to Talk With Your Family Members About Your hATTR Diagnosishttps://www.oneamyloidosisvoice.com/wp-c...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
